{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:01:32Z","timestamp":1790017292835,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"DOI":"10.1038\/s41386-026-02562-4","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:15:17Z","timestamp":1790014517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7062-8192","authenticated-orcid":false,"given":"Balwinder","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3778-5499","authenticated-orcid":false,"given":"Hossam M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Miola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4212-7424","authenticated-orcid":false,"given":"Manoela V.","family":"Foga\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-5239","authenticated-orcid":false,"given":"Luke A.","family":"Jelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Prokop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-8829","authenticated-orcid":false,"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6997-4215","authenticated-orcid":false,"given":"Mark A.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-7776","authenticated-orcid":false,"given":"John D.","family":"Port","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2562_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120299","volume":"393","author":"Z Zhang","year":"2026","unstructured":"Zhang Z, Chen X, Wu S, Chen X, Wang X, Liu C, et al. Global, regional and national burden of anxiety and depression disorders from 1990 to 2021, and forecasts up to 2040. J Affect Disord. 2026;393:120299.","journal-title":"J Affect Disord"},{"key":"2562_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fncel.2019.00087","volume":"13","author":"MV Fogaca","year":"2019","unstructured":"Fogaca MV, Duman RS. Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions. Front Cell Neurosci. 2019;13:87.","journal-title":"Front Cell Neurosci"},{"key":"2562_CR3","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1002\/hbm.23244","volume":"37","author":"RR Schur","year":"2016","unstructured":"Schur RR, Draisma LW, Wijnen JP, Boks MP, Koevoets MG, Joels M, et al. Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies. Hum Brain Mapp. 2016;37:3337\u201352.","journal-title":"Hum Brain Mapp"},{"key":"2562_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","volume":"102","author":"RS Duman","year":"2019","unstructured":"Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019;102:75\u201390.","journal-title":"Neuron"},{"key":"2562_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0165-0327(95)00025-I","volume":"34","author":"F Petty","year":"1995","unstructured":"Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord. 1995;34:275\u201381.","journal-title":"J Affect Disord"},{"key":"2562_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/mp.2010.120","volume":"16","author":"B Luscher","year":"2011","unstructured":"Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16:383\u2013406.","journal-title":"Mol Psychiatry"},{"key":"2562_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.nic.2019.09.002","volume":"30","author":"JD Port","year":"2020","unstructured":"Port JD. Magnetic Resonance Spectroscopy for Psychiatry: Progress in the Last Decade. Neuroimaging Clin N Am. 2020;30:25\u201333.","journal-title":"Neuroimaging Clin N Am"},{"key":"2562_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1176\/appi.ajp.159.4.663","volume":"159","author":"G Sanacora","year":"2002","unstructured":"Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159:663\u20135.","journal-title":"Am J Psychiatry"},{"key":"2562_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1176\/appi.ajp.160.3.577","volume":"160","author":"G Sanacora","year":"2003","unstructured":"Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry. 2003;160:577\u20139.","journal-title":"Am J Psychiatry"},{"key":"2562_CR10","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1503\/jpn.150223","volume":"41","author":"MJ Dubin","year":"2016","unstructured":"Dubin MJ, Mao X, Banerjee S, Goodman Z, Lapidus KA, Kang G, et al. Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. J Psychiatry Neurosci. 2016;41:E37\u201345.","journal-title":"J Psychiatry Neurosci"},{"key":"2562_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41386-024-02002-1","volume":"50","author":"MV Fogaca","year":"2025","unstructured":"Fogaca MV, Daher F, Picciotto MR. Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses. Neuropsychopharmacology. 2025;50:673\u201384.","journal-title":"Neuropsychopharmacology"},{"key":"2562_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2021.111432","volume":"320","author":"B Singh","year":"2022","unstructured":"Singh B, Port JD, Pazdernik V, Coombes BJ, Vande Voort JL, Frye MA. Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: A pilot study. Psychiatry Res Neuroimaging. 2022;320:111432.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"2562_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113953","volume":"301","author":"B Singh","year":"2021","unstructured":"Singh B, Port JD, Voort JLV, Coombes BJ, Geske JR, Lanza IR, et al. A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. Psychiatry Res. 2021;301:113953.","journal-title":"Psychiatry Res"},{"key":"2562_CR14","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021;18:e1003583.","journal-title":"PLoS Med"},{"key":"2562_CR15","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/s41386-018-0136-3","volume":"43","author":"CG Abdallah","year":"2018","unstructured":"Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018;43:2154\u201360.","journal-title":"Neuropsychopharmacology"},{"key":"2562_CR16","unstructured":"Rohatgi A. WebPlotDigitizer (Version 5.2) https:\/\/automeris.io."},{"key":"2562_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/bdi.13366","volume":"26","author":"B Singh","year":"2024","unstructured":"Singh B, Yocum AK, Strawbridge R, Burdick KE, Millett CE, Peters AT, et al. Patterns of pharmacotherapy for bipolar disorder: A GBC survey. Bipolar Disord. 2024;26:22\u201332.","journal-title":"Bipolar Disord"},{"key":"2562_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"2562_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u201316.","journal-title":"ANZ J Surg"},{"key":"2562_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/JCP.0000000000001317","volume":"41","author":"B Joseph","year":"2021","unstructured":"Joseph B, Parsaik AK, Ahmed AT, Erwin PJ, Singh B. A Systematic Review on the Efficacy of Intravenous Racemic Ketamine for Bipolar Depression. J Clin Psychopharmacol. 2021;41:71\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"2562_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102493","volume":"4","author":"SM Frank","year":"2023","unstructured":"Frank SM, Becker M, Malloni WM, Sasaki Y, Greenlee MW, Watanabe T. Protocol to conduct functional magnetic resonance spectroscopy in different age groups of human participants. STAR Protoc. 2023;4:102493.","journal-title":"STAR Protoc"},{"key":"2562_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neuroimage.2012.12.004","volume":"86","author":"PG Mullins","year":"2014","unstructured":"Mullins PG, McGonigle DJ, O\u2019Gorman RL, Puts NA, Vidyasagar R, Evans CJ, et al. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. NeuroImage. 2014;86:43\u201352.","journal-title":"NeuroImage"},{"key":"2562_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.neuroimage.2013.07.049","volume":"85","author":"N Lally","year":"2014","unstructured":"Lally N, Mullins PG, Roberts MV, Price D, Gruber T, Haenschel C. Glutamatergic correlates of gamma-band oscillatory activity during cognition: a concurrent ER-MRS and EEG study. NeuroImage. 15;85 Pt 2:823\u201333.","journal-title":"NeuroImage"},{"key":"2562_CR24","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/s41591-025-03800-w","volume":"31","author":"LA Jelen","year":"2025","unstructured":"Jelen LA, Lythgoe DJ, Stone JM, Young AH, Mehta MA. Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study. Nat Med. 2025;31:2958\u201366.","journal-title":"Nat Med"},{"key":"2562_CR25","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Chapter 10, Analysing data and undertaking meta-analyses. Second ed. John Wiley & Sons; 2019.","DOI":"10.1002\/9781119536604"},{"key":"2562_CR26","unstructured":"Team RCR. Language definition. Vienna, Austria: R Found Stat Comput. 2000;3:116."},{"key":"2562_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"2562_CR28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968\u201380.","journal-title":"Neuroimage"},{"key":"2562_CR29","first-page":"466","volume":"3","author":"AM Mowinckel","year":"2020","unstructured":"Mowinckel AM, Vidal-Pi\u00f1eiro D. Visualization of Brain Statistics With R Packages ggseg and ggseg3d. Adv Methods Pract Psychol Sci. 2020;3:466\u201383.","journal-title":"Adv Methods Pract Psychol Sci"},{"key":"2562_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","volume":"191","author":"GW Valentine","year":"2011","unstructured":"Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011;191:122\u20137.","journal-title":"Psychiatry Res"},{"key":"2562_CR31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1017\/S1461145711001593","volume":"15","author":"G Salvadore","year":"2012","unstructured":"Salvadore G, van der Veen JW, Zhang Y, Marenco S, Machado-Vieira R, Baumann J, et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol. 2012;15:1063\u201372.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2562_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jad.2025.04.165","volume":"383","author":"Y Ohtani","year":"2025","unstructured":"Ohtani Y, Tani H, Honda S, Nomoto-Takahashi K, Yatomi T, Yonezawa K, et al. Glutamate plus glutamine to GABA ratio as a predictor of ketamine response in treatment-resistant depression: A double-blind, randomized, open-label extension study. J Affect Disord. 2025;383:354\u201362.","journal-title":"J Affect Disord"},{"key":"2562_CR33","doi-asserted-by":"publisher","first-page":"e2013211","DOI":"10.1001\/jamanetworkopen.2020.13211","volume":"3","author":"MS Milak","year":"2020","unstructured":"Milak MS, Rashid R, Dong Z, Kegeles LS, Grunebaum MF, Ogden RT, et al. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e2013211.","journal-title":"JAMA Netw Open"},{"key":"2562_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mp.2015.83","volume":"21","author":"MS Milak","year":"2016","unstructured":"Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry. 2016;21:320\u20137.","journal-title":"Mol Psychiatry"},{"key":"2562_CR35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/ijnp\/pyac049","volume":"25","author":"A Weigand","year":"2022","unstructured":"Weigand A, Gartner M, Scheidegger M, Wyss PO, Henning A, Seifritz E, et al. Predicting Antidepressant Effects of Ketamine: the Role of the Pregenual Anterior Cingulate Cortex as a Multimodal Neuroimaging Biomarker. Int J Neuropsychopharmacol. 2022;25:1003\u201313.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2562_CR36","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41386-018-0057-1","volume":"43","author":"JW Evans","year":"2018","unstructured":"Evans JW, Lally N, An L, Li N, Nugent AC, Banerjee D, et al. 7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study. Neuropsychopharmacology. 2018;43:1908\u201314.","journal-title":"Neuropsychopharmacology"},{"key":"2562_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.70102","volume":"104","author":"S Njau","year":"2026","unstructured":"Njau S, Zavaliangos-Petropulu A, Joshi S, Brooks J, O\u2019Neill J, Roger WP, et al. Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment-Resistant Depression. J Neurosci Res. 2026;104:e70102.","journal-title":"J Neurosci Res"},{"key":"2562_CR38","doi-asserted-by":"publisher","first-page":"111455","DOI":"10.1016\/j.pnpbp.2025.111455","volume":"141","author":"K Godfrey","year":"2025","unstructured":"Godfrey K, Douglass H, Erritzoe D, Muthukumaraswamy S, Nutt D, Sumner R. The role of GABA, glutamate, and Glx levels in treatment of major depressive disorder: A systematic review and meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2025;141:111455.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2562_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41386-021-01101-7","volume":"47","author":"DA Pizzagalli","year":"2022","unstructured":"Pizzagalli DA, Roberts AC. Prefrontal cortex and depression. Neuropsychopharmacology. 2022;47:225\u201346.","journal-title":"Neuropsychopharmacology"},{"key":"2562_CR40","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S0140-6736(11)60602-8","volume":"379","author":"DJ Kupfer","year":"2012","unstructured":"Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. 2012;379:1045\u201355.","journal-title":"Lancet"},{"key":"2562_CR41","doi-asserted-by":"crossref","unstructured":"Yoon G, Pittman B, Ralevski E, Petrakis IL, Krystal JH. Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: a randomized controlled trial. Int J Neuropsychopharmacol. 2025;28:pyaf056.","DOI":"10.1093\/ijnp\/pyaf056"},{"key":"2562_CR42","doi-asserted-by":"crossref","unstructured":"Bandeira ID, Jelen LA, Tucciarone JM, Heifets BD, Rodriguez CI, Schatzberg AF. Methodological considerations for interpreting ketamine-naltrexone trials in depression. Int J Neuropsychopharmacol. 2025;28:pyaf073.","DOI":"10.1093\/ijnp\/pyaf073"},{"key":"2562_CR43","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. Am J Psychiatry. 2018;175:1205\u201315.","journal-title":"Am J Psychiatry"},{"key":"2562_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"G Yoon","year":"2019","unstructured":"Yoon G, Petrakis IL, Krystal JH. Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder. JAM A Psychiatry. 2019;76:337\u201338.","journal-title":"JAM A Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02562-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02562-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02562-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:15:20Z","timestamp":1790014520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02562-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":44,"alternative-id":["2562"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02562-4","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Singh\n                      has received research grant support from Mayo Clinic, the National Network of Depression Centers (NNDC), Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2) and NIH. He is a KL2 Mentored Career Development Program scholar, supported by CTSA Grant Number KL2 TR002379 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.\n                      Dr. Zarate\n                      is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2\u2009R,6\u2009R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2\u2009R,6\u2009R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorder. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH; ZIAMH002927). The contributions of the NIH author are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author and do not necessarily reflect the views of the NIH or the US Department of Health and Human Services.\n                      Dr. Port\n                      serves as an imaging consultant to Bioclinica (unrelated to the current study).\n                      Dr. Frye\n                      reports received grant support from Assurex Health, Baszucki Group, Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), and Mayo Foundation. He is a consultant for Carnot Laboratories and the American Physician Institute, from which he has received CME\/travel supports and honoraria. He also has a financial interest in Chymia LLC through stock ownership and royalties.\n                      Dr. Sanacora\n                      in the past 24 months has received grants\/research contracts from Michael J Foxx Foundation, Merck, National Institutes of Health, and Patient Centered Outcomes Research Institute. He also served as consultant to AbbVie, Actinogen Medical, Alto Neuroscience, Atai, Allumis, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Clexio, Denovo Biopharma, Douglas Pharmaceuticals, EMA Wellness, Embark, Freedom Biosciences, GH Research, Gilgamesh, Holmusk, Janssen, Lilly, Merck, Neumora, Neurocrine, Newleos, Novartis, Relmada Therapeutics, Seaport Pharmaceuticals, Supernus, Tetricus, and Transcend Therapeutics. He also holds equity in Biohaven Pharmaceuticals, Freedom Biosciences, Gilead, Oui Therapeutics, Relmada, and Tetricus. He is a co-inventor on a US patents (#8,778,979), (#11554117), (#10052318) (#11793794) and (#12090145). Yale University has a financial relationship with Janssen Pharmaceuticals and may receive financial benefits from this relationship. Dr. Sanacora receives no benefit from this agreement and the University has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University\u2019s Conflict of Interest office. Other authors have none to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}